|
Method of Treating HFpEF
This technology is directed to a method of treating heart failure with preserved ejection fraction (HFpEF) by using a compound that mimics the effect of titin phosphorylation at the N2B segment. This technology has the potential to discover drugs for treating heart failure patients with stiff hearts and declined filling capacity.
Background:
About...
Published: 2/23/2026
|
Inventor(s): Hendrikus Granzier
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Life Sciences > Therapeutics
|
|
Inhibitory Monoclonal Antibodies Against Factor XII(a) and Method of use for Treatment of Dilated Cardiomyopathy and Heart Failure
This invention details how to make and utilize monoclonal antibodies that bind to and inhibit the activity of the coagulation factor Factor XII (FXII, FXIIa) protein, and methods of use for treatment of dilated cardiomyopathy and heart failure.
Background:
Approximately 6.7 million Americans over 20 years of age experience heart failure, and the prevalence...
Published: 2/2/2026
|
Inventor(s): Inna Gladysheva, Guy Reed
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Life Sciences > Biologics, Technology Classifications > Life Sciences > Therapeutics
|
|
Inhibition of Metastasis in Triple Negative Breast Cancer
This invention uses a therapeutic peptide sequence that inhibits breast cancer metastasis by activating natural killer (NK) cells against breast cancer cells. This inhibitor can be used to treat triple-negative breast cancer metastasis, associated with excess epidermal growth factor receptor (EGRF) which is overexpressed and amplified in 60% of triple-negative...
Published: 1/21/2026
|
Inventor(s): Joyce Schroeder
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Healthcare Portfolios > Women's Health, Technology Classifications > Life Sciences > Therapeutics
|
|
Therapeutic Target of Ewing Sarcoma by G-Quadruplex Binding Compound
This innovation identified lead molecules that target specific nucleic acid structures involved with forming G-Quadruplex structures. These G-Quadruplex structures are a highly stable nucleic acid fold with planar stacks of guanine tetrads which regulate genome stability, transcription, and telomere maintenance. This innovation details a therapeutic...
Published: 1/6/2026
|
Inventor(s): Jacob Schwartz, Haining Zhu, Ajibola Adelekun, Valery Thompson
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology
|
|
Novel Therapy for Ischemic and Pressure-Overload Heart Diseases
This novel therapy involves using valosin-containing protein (VCP) to prevent or treat ischemic and pressure overload-induced heart disease. Inactivation and reduced VCP expression are highly associated with multiple cardiac diseases. Overexpression of VCP in the heart has been found to reduce infarct size during ischemia-reperfusion injury and also...
Published: 12/12/2025
|
Inventor(s): Hongyu Qiu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Life Sciences > Biologics, Technology Classifications > Life Sciences > Therapeutics
|
|
A Flexible, Scalable Platform Technology to Augment Antibiotic Efficacy
This invention relates to a novel, safe, and efficacious approach to reduce antibiotic concentrations required to kill pathogenic bacteria. The product thus augments antibiotic efficacy, including against bacteria that are clinically resistant.
Background:
One of the biggest risks to global public health is antibiotic resistance. Through processes...
Published: 12/1/2025
|
Inventor(s): Gayatri Vedantam, Virinchipuram Viswanathan, Arun Sharma, David Stewart
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics
|
|
Novel Mechanism-Based Therapy for Aortic Stiffening and Related Cardiovascular and Cerebrovascular Disorders
This invention involves a novel mechanism-based therapy by using a small molecule compound to reduce aging and hypertensive aortic stiffening, subsequently improve blood pressure (BP) control in resistant hypertension patients and prevent or reverse pathologies of vascular cognitive impairment and dementia (VCID) and Alzheimer’s Disease (AD)....
Published: 11/24/2025
|
Inventor(s): Hongyu Qiu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Repurposing the FDA-Approved Antibody to Treat Aortic Stiffening and Resistant Hypertension
This innovation repurposes an FDA-approved antibody to treat and prevent aortic stiffening and resistant hypertension (RH). This mechanism-based therapeutic, inhibits receptor mediated inflammatory and pro-stiffness signaling to reduce aortic stiffness and improve blood pressure control, ultimately breaking the root cycle of hypertension.
Background:...
Published: 11/24/2025
|
Inventor(s): Hongyu Qiu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Life Sciences > Biologics, Technology Classifications > Life Sciences > Therapeutics
|
|
A Precision Anti-Infective for Enterococcus sp Eradication as well as Selective Decontamination
This innovation is a water-soluble nanocarrier that can precisely and quickly eradicate the healthcare-associated pathogen enterococci. The carrier can complex with oligonucleotides that can bind to bacterial mRNA, preventing translation and inhibiting bacterial functions of enterococci. It is also non-toxic to both human tissue and bacteria and may...
Published: 10/20/2025
|
Inventor(s): Gayatri Vedantam, Virinchipuram Viswanathan, Arun Sharma, David Stewart
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
The Use of Cold Plasma to Facilitate CRISPR
This technology is a compact, automated cold plasma generator engineered to enable safe and efficient delivery of CRISPR-Cas9 into cells without chemical reagents. Through the use of cold plasma, cell membranes are transiently permeabilized, creating a controlled pathway for the entry of gene-editing components. This approach directly addresses critical...
Published: 10/9/2025
|
Inventor(s): Sara Sheikhlary
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios, Technology Classifications > Life Sciences > Therapeutics
|
